A survival analysis stratified by demographic and clinical characteristics revealed an OS benefit was observed with across key subgroups.
Andrea Eleazar, MHS
Advertisement
Articles by Andrea Eleazar, MHS
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Frontline Alectinib Upholds OS Benefit in Advanced ALK+ NSCLC
2
Sevabertinib Monotherapy Elicits Durable Responses in HER2-Mutant NSCLC
3
Episode 16: Anticipated ESMO 2025 Data That May Change GU Oncology
4
Zongertinib Maintains Efficacy Benefit in First-line HER2-Mutated NSCLC
5
